Carna Biosciences (TSE:4572) Intangible Assets: 円0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4572 Carna Biosciences Inc TSE:4572
27 GF Score
Price 円408.00
GF Value 円203.63
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Carna Biosciences Intangible Assets?

Carna Biosciences TSE:4572 -0.24% 27 Intangible Assets is 円0.0 Mil as of Jun. 2026. GuruFocus rates TSE:4572 with a GF Score™ of 27/100 and a GF Value™ of 円203.63 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Carna Biosciences's intangible assets for the quarter that ended in Jun. 2026 was 円0.0 Mil.


Carna Biosciences  (TSE:4572) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Carna Biosciences Intangible Assets Related Terms


Carna Biosciences Intangible Assets Historical Data

* Premium members only.

The historical data trend for Carna Biosciences's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carna Biosciences Intangible Assets Chart

Carna Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Intangible Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.74 1.92 1.09 0.00 0.00

Carna Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4572
27GF Score
Carna Biosciences Inc TSE:4572
Intangible Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carna Biosciences Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.

Frequently Asked Questions Learn more about Intangible Assets →
What does a Intangible Assets of 円0.0 Mil mean?
Carna Biosciences (TSE:4572) has a Intangible Assets of 円0.0 Mil as of Jun. 2026. Intangible assets include patents, goodwill and trade secrets. View historical data on Carna Biosciences and its competitors.
Is Carna Biosciences' Intangible Assets too high?
Carna Biosciences' current Intangible Assets is 円0.0 Mil. Overall, Carna Biosciences has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Carna Biosciences' Intangible Assets compare to VRTX and REGN?
Carna Biosciences' Intangible Assets of 円0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intangible Assets for a Biotechnology company?
A good Intangible Assets depends on the Biotechnology industry context. However, Intangible Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intangible Assets mean?
A high Intangible Assets can signal that a stock is expensive relative to its fundamentals. Intangible assets include patents, goodwill and trade secrets. View historical data on Carna Biosciences and its competitors. Carna Biosciences's current Intangible Assets is 円0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carna Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Carna Biosciences (TSE:4572) is currently considered Significantly Overvalued. The stock's GF Value™ is 円203.63, compared to a current price of 円408.00 — trading 100.4% above its estimated fair value. The current Intangible Assets is 円0.0 Mil. Carna Biosciences' overall GF Score™ is 27/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intangible Assets calculated?
Intangible Assets is calculated from a company's financial statements. For Carna Biosciences (TSE:4572), the current Intangible Assets is 円0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carna Biosciences (TSE:4572) Overvalued in 2026?

Based on GuruFocus' analysis, Carna Biosciences stock appears to be overvalued. The current stock price of 円408.00 is trading 100.4% above its estimated GF Value™ of 円203.63. GuruFocus considers Carna Biosciences to be Significantly Overvalued.

Key valuation signals for TSE:4572:

  • Intangible Assets: 円0.0 Mil
  • GF Value™: 円203.63 vs. price of 円408.00 (100.4% above fair value)
  • GF Score™: 27/100 with 7 warning signs

No single metric tells the full story. See the TSE:4572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Carna Biosciences Business Description

Address BMA 3F 1-5-5 Minatojima-Minamimachi, Kobe, JPN, 650-0047
Carna Biosciences Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines for the treatment of cancer and inflammatory diseases using own kinase drug discovery platform, QuickScout.
27GF Score

Get the complete analysis for TSE:4572

Intangible Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円408.00
Price
円203.63
GF Value